

Table S1: A Selection Of Past Studies Investigating Remission In SLE

Author, year	Cohort	n	min. duration years	A M	CS	IS	PGA	clinical SLEDAI	SA	Rem. %	Duration of remission	Predictors of remission (Positive/Negative)
Zen, et al., 2015	all C	224	5	Y	N	N	ND	0	N	7.1	ND	Neg. in multi-variable models: glomerulonephritis, vasculitis, hematological activity
					N	Y	ND	0	Y	14.7		
					1-5mg/d	Y	ND	0	Y	15.6		
Steiman, et al., 2014	ND	1613	5	Y	N	N	ND	0	Y	2.4	Mean ± SD: 11.5 ± 6.4 years	Pos. in case control-study: Caucasian cases, lower SLEDAI-2K at first visit, lower AMS until remission onset, less skin, CNS and pulmonary manifestations, lower CS dose and cumulative CS dose at start or remission, lower IS dose Logistic regression: none Neg in stepwise regression: dermatological involvement, older age at diagnosis
				Y	Y	Y	ND	0	Y	2.1	Mean ± SD: 8.5 ± 2.9 years Range: 5.1 - 16.6 years	
Conti, et al., 2012	ND	45	2	Y	N	N	ND	0	Y (all)	2.2	ND	ND
Nossent, et al., 2010	Euro	200	none	ND	ND	ND	Y (no cutoff)	ND	ND	27.5	ND, 49% achieving remission maintained over 5-year follow-up	Pos. in uni-variable analyses: lower CS dose in first year, lower initial SLEDAI, lower SDI at the end of first year
Urowitz, et al., 2005	ND	703	5	N	N	N	ND	0	N	1.7	Mean ± SD: 7.1 ± 5.3 years Median: 6 years Range: 5 - 17 years	Neg. in case-control study: young age at diagnosis, longer disease duration at study, cutaneous or CNS involvement, higher AMS, anti-ds DNA, anti-cardiolipin
				Y	Y	Y	ND	0	Y	1.8	ND	
				N	N	N	ND	0	N	6.5	Mean ± SD: 1.8 ± 0.9 years	
				Y	Y	Y	ND	0	Y	18.9	ND	
Formiga, et al., 1999	ND	100	1	N	N	N	ND	ND	Y	24	Mean: 55 months Range: 24 - 120 months	Case control study: no differences in baseline characteristics including SLE organ involvement or SLEDAI Neg. in uni-variable analysis: high SLEDAI
Barr, et al., 1999	AA: 58 C: 42	204	1	ND	ND	ND	<1.0	0	Y	28.4	Mean ± SD: 2.3 ± 1.1 years Range: 1.0 - 5.7 years	ND
Drenkhard, et al., 1996	Mex	667	1	N	N	N	ND	ND	Y	23	Mean ± SD: 4.6 ± 3.6 years Range: 1 - 17.3 years Mean total time ± SD: 5.8 ± 4.0 years 40 ± 24% of total disease duration	ND

N: number of SLE patients , ND: not described, AM: antimalarials, CS: corticosteroids, IS: immunosuppressives, PGA: Physician global assessment, SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, SA: serological activity, SD: standard deviation, Pos.: positive predictors of remission, Neg.: negative predictors of remission, SDI: SLICC/ACR Damage Index, neg: negative predictors of remission, Y: yes, N: no, C: Caucasian, Euro: European, AA: African American, Mex: Mexican